4
November
2014

Consortium members: Partner 1: Bio-UR, Switzerland, St. Petersburg State Chemical-Pharmaceutical Academy.
The aim is to develop innovative drugs and functional foods in synergy with the use of biotechnology culturing cellulolytic fungi hybrid with known pharmacological activity in higher biomass medicinal plants to obtain suspension cell culture method with a minimum amount of roughage.
Companies Bio-UR and "BIOFARMOS" have wide experience in the innovation process of mushroom cultivation with known pharmacological properties. St. Petersburg State Chemical-Pharmaceutical Academy offers innovative research and diagnostic / therapeutic tools to determine the toxicity and safety studies, as well as for the treatment of diabetes.
Companies will work together to develop and optimize biotechnology of mycelium biomass and to grow fruiting bodies of fungi on the rare medicinal plants. This hybrid method of biotechnology will help to understand 1) whether the conversion of one compound is possible 2) how to obtain new compounds 3)and also additive and synergistic activity of the compounds. Hereinafter for Russia and the EU will be developed new functional foods / food supplements on the basis of the resulting formulation.